Head-To-Head Survey: Rockwell Medical (NASDAQ:RMTI) & Delcath Systems (NASDAQ:DCTH)

Rockwell Medical (NASDAQ:RMTI) and Delcath Systems (NASDAQ:DCTH) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Profitability

This table compares Rockwell Medical and Delcath Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rockwell Medical	-7.33%	-14.03%	-8.90%
Delcath Systems	6.05%	5.78%	5.18%

Volatility & Risk

Rockwell Medical has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Rockwell Medical and Delcath Systems, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rockwell Medical	2	0	1	0	1.67
Delcath Systems	0	2	2	0	2.50

Rockwell Medical currently has a consensus price target of $20.00, indicating a potential upside of 173.60%. Delcath Systems has a consensus price target of $29.33, indicating a potential upside of 45.94%. Given Rockwell Medical’s higher possible upside, research analysts clearly believe Rockwell Medical is more favorable than Delcath Systems.

Insider and Institutional Ownership

23.3% of Rockwell Medical shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 4.6% of Rockwell Medical shares are owned by company insiders. Comparatively, 19.4% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Rockwell Medical and Delcath Systems”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rockwell Medical	$69.26 million	0.43	-$5.31 million	($1.34)	-5.46
Delcath Systems	$85.23 million	8.18	$2.70 million	$0.01	2,010.00

Delcath Systems has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Summary

Delcath Systems beats Rockwell Medical on 11 of the 13 factors compared between the two stocks.

About Rockwell Medical

Rockwell Medical, Inc. is a healthcare company focused on developing, manufacturing and commercializing products used in the treatment of patients with end-stage renal disease (ESRD) who receive hemodialysis. The company supplies products intended to support anemia management and other aspects of dialysis care. Its principal pharmaceutical product is Triferic, an iron replacement therapy designed to deliver iron to hemodialysis patients through the dialysate. Rockwell Medical also markets Triferic AVNU, an intravenous formulation administered during hemodialysis.

About Delcath Systems

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.